Silver X says Q3 AgEq processed rises 42% year over year at Nueva Recuperada plant
Bitget2026/10/08 11:35Silver X reported 3Q26 production at Nueva Recuperada, with processed tonnage up 63% to 54,681 MT. Ore mined rose 113% to 60,694 MT, with throughput averaging 594 tpd during the 1,000 tpd expansion. Gold ounces processed increased 119% to 1,641 oz, with head grades up 34% to 0.93 g/t. Silver ounces processed climbed 47% to 138,724 oz; AgEq processed rose 42% to 322,822 oz. AgEq produced increased 35% to 225,237 oz; processed tonnage fell 12% from 2Q26 due to expansion work. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silver X Mining Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610080735ACCESSWRNAPR_____1234153) on October 08, 2026, and is solely responsible for the information contained therein.
- Silver X reported 3Q26 production at Nueva Recuperada, with processed tonnage up 63% to 54,681 MT.
- Ore mined rose 113% to 60,694 MT, with throughput averaging 594 tpd during the 1,000 tpd expansion.
- Gold ounces processed increased 119% to 1,641 oz, with head grades up 34% to 0.93 g/t.
- Silver ounces processed climbed 47% to 138,724 oz; AgEq processed rose 42% to 322,822 oz.
- AgEq produced increased 35% to 225,237 oz; processed tonnage fell 12% from 2Q26 due to expansion work.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
JPMorgan maintains "Neutral" rating on Johnson & Johnson (JNJ.US): Strong data from two anti-cancer drugs, but valuation premium limits upside potential
Johnson & Johnson’s new prostate cancer drug and head and neck cancer drug Ervantumab both released positive data at ESMO. JPMorgan stated that the pipeline shows differentiated potential but valuations are relatively high, maintaining a Neutral rating.
AI trading hype fades and product competition intensifies: SK Hynix (SKHY.US) leveraged ETF delisted from US stock market and liquidated just three months after launch
Two U.S. leveraged ETFs linked to SK Hynix (SKHY.US)—the Tradr 2X Long SK Hynix Daily ETF and the Tradr 2X Short SK Hynix Daily ETF—will be liquidated around November 12, approximately three months after their listing on July 28.
Australian Dollar bulls seem hesitant below one-month top before Aussie CPI, FOMC meeting
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.
Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.
Crypto prices
More
